Regado Reports Positive Results from Anticoagulation Drug Study

Rates of bleeding were lower in the 75% and 100% reversal arms than heparin. In addition, the incidence of ischaemic events was lower in REG1 treated patients compared with those treated with heparin.

Regado Biosciences has received positive primary results from the Phase IIb RADAR clinical trial of its REG1 anticoagulation system. REG1 is a two-component system consisting of pegnivacogin, a highly selective Factor IXa (FIXa) inhibitor and anivamersen, its complementary specific active-control agent.

The study results showed that ACUITY (Acute Catheterisation and Urgent Intervention Triage Strategy) major bleeding following immediate sheath removal exhibited a dose response with bleeding rates decreasing with increasing levels of reversal.

Rates of bleeding were lower in the 75% and 100% reversal arms than heparin. In addition, the incidence of ischaemic event